HF
PRLD icon

HRT Financial’s Prelude Therapeutics PRLD Stock Holding History

HRT Financial’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-58,699
Closed -$200K – 5108
2026
Q1 		$200K Buy
+58,699
New +$154K ﹤0.01% 3199
2025
Q4 		– Sell
-16,901
Closed -$24K – 3849
2025
Q3 		$24K Buy
+16,901
New +$16.9K ﹤0.01% 2685
2023
Q2 		– Sell
-22,175
Closed -$126K – 3100
2023
Q1 		$126K Buy
+22,175
New +$135K ﹤0.01% 2021
2022
Q1 		– Sell
-114,249
Closed -$1.42M – 3700
2021
Q4 		$1.42M Buy
114,249
+98,690
+634% +$1.61M 0.01% 873
2021
Q3 		$486K Buy
+15,559
New +$504K ﹤0.01% 2022

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

HRT Financial's PRLD Position: Q2 2026 in Review

HRT Financial sold out of Prelude Therapeutics (PRLD) in Q2 2026, closing a stake of 58,699 shares — an estimated $200K sold.

HRT Financial first reported a position in PRLD in Q3 2021 and held it in 5 quarters. The position peaked at $1.42M in Q4 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • HRT Financial reported no remaining Prelude Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 58,699 Prelude Therapeutics shares in Q2 2026, an estimated $200K.
  • HRT Financial first reported a position in Prelude Therapeutics in Q3 2021 and held it in 5 quarters.
  • HRT Financial's Prelude Therapeutics position peaked at $1.42M in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.